Indefinite Delivery Contract SPE2DX16D2922

The Indefinite Delivery Contract (IDC) SPE2DX16D2922 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The single-award IDC, valued at up to $4,999,999.99, runs through December 31, 2025 and serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contracted items include specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains such as cardiovascular health, diabetes management, mental health, pain management, infectious disease prevention, and general medical care. Amerisourcebergen also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs. These IDCs enable the efficient government procurement of essential pharmaceutical and medical supplies to serve the healthcare needs of military personnel, veterans, and other federal beneficiaries.

The parent company, Cencora, Inc., doing business as Amerisourcebergen, is a major pharmaceutical distribution company that provides a wide range of pharmaceutical products and medical supplies to the U.S. federal government, with a focus on supporting the Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems. Cencora, Inc. holds a significant IDC with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide.